Invasive Escherichia Coli Disease

General Information

Extraintestinal pathogenic Escherichia coli (ExPEC) is a leading cause of community-onset and healthcare-associated invasive disease particularly in adults over 60 years old.

Increasing multidrug resistance among ExPEC strains constitutes a major obstacle to treatment and is implicated in increasing numbers of hospitalisations and deaths and increasing healthcare costs associated with ExPEC infections.

ExPEC strains have a great impact on public health and economic burden due to the high incidence of ExPEC infections and its antimicrobial resistance.

Transmission

Foodborne, waterborne and sexually-transmitted disease.

Symptoms

ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of adult sepsis and bacteremia, and is the second most common cause of neonatal meningitis.

Epidemiology

ExPEC is responsible for 70–95% of community-onset UTIs and approximately 50% of nosocomial UTIs, hence accounting for substantial morbidity, mortality, and medical expenses.

Vaccines Pipeline

1
Vaccines in
the pipeline

TECHNOLOGY PLATFORMS

Glycoconjugate vaccine (1)

DEVELOPMENT PHASES

Phase III (1)

TRIAL POPULATION

Older Adults (1)

Source:
Poolman JT, Wacker M. Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. The Journal of infectious diseases. 2016; 213(1)
Duan Y, Gao H, Zheng L, Liu S, Cao Y, Zhu S, et al. Antibiotic resistance and virulence of extraintestinal pathogenic Escherichia coli (ExPEC) vary according to molecular types. Frontiers in Microbiology. 2020
Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Frontiers in microbiology. 2012.
Geurtsen J, de Been M, Weerdenburg E, Zomer A, McNally A, Poolman J. Genomics and pathotypes of the many faces of Escherichia coli. FEMS microbiology reviews. 2022; 46(6).